These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29546433)

  • 1. Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore.
    Tee A; Chow WL; Burke C; Guruprasad B
    Singapore Med J; 2018 Jul; 59(7):383-389. PubMed ID: 29546433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
    Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.
    Reza Maleki-Yazdi M; Molimard M; Keininger DL; Gruenberger JB; Carrasco J; Pitotti C; Sauvage E; Chehab S; Price D
    Appl Health Econ Health Policy; 2016 Oct; 14(5):579-94. PubMed ID: 27516088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.
    Bjermer L; van Boven JFM; Costa-Scharplatz M; Keininger DL; Gutzwiller FS; Lisspers K; Mahon R; Olsson P; Roche N
    Respir Res; 2017 Dec; 18(1):206. PubMed ID: 29228950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.
    Skoupa J; Kasak V; Klimes J; Valena T
    Value Health Reg Issues; 2018 Sep; 16():112-118. PubMed ID: 30539739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
    Chan MC; Tan EC; Yang MC
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1079-1088. PubMed ID: 29670344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
    COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
    Wedzicha JA; Zhong N; Ichinose M; Humphries M; Fogel R; Thach C; Patalano F; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():339-349. PubMed ID: 28176893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
    Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
    Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
    Vogelmeier C; Zhong N; Humphries MJ; Mezzi K; Fogel R; Bader G; Patalano F; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3189-3197. PubMed ID: 28008244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
    Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
    Frith PA; Ashmawi S; Krishnamurthy S; Gurgun A; Hristoskova S; Pilipovic V; Hamann AM; Backer A; Olsson P; Kostikas K; Diaz DV;
    Respirology; 2018 Dec; 23(12):1152-1159. PubMed ID: 30074294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
    Anzueto AR; Kostikas K; Mezzi K; Shen S; Larbig M; Patalano F; Fogel R; Banerji D; Wedzicha JA
    Respir Res; 2018 Jun; 19(1):121. PubMed ID: 29925383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach.
    Lakhotia B; Mahon R; Gutzwiller FS; Danyliv A; Nikolaev I; Thokala P
    Int J Chron Obstruct Pulmon Dis; 2020; 15():787-797. PubMed ID: 32368025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
    Anzueto AR; Vogelmeier CF; Kostikas K; Mezzi K; Fucile S; Bader G; Shen S; Banerji D; Fogel R
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1325-1337. PubMed ID: 28496316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
    Wedzicha JA; Singh D; Tsiligianni I; Jenkins C; Fucile S; Fogel R; Shen S; Goyal P; Mezzi K; Kostikas K
    Respir Res; 2019 Jan; 20(1):4. PubMed ID: 30621717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
    Vogelmeier CF; Chapman KR; Miravitlles M; Roche N; Vestbo J; Thach C; Banerji D; Fogel R; Patalano F; Olsson P; Kostikas K; Wedzicha JA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1125-1134. PubMed ID: 29692607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year.
    Mangia PP; Gallo O; Ritrovato D; Pradelli L
    Clin Drug Investig; 2021 Sep; 41(9):785-794. PubMed ID: 34333742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.
    Tsiligianni I; Mezzi K; Fucile S; Kostikas K; Shen S; Banerji D; Fogel R
    COPD; 2017 Aug; 14(4):375-381. PubMed ID: 28594587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.